News

Téléthon 2022: Benjamin, a hope for families thanks to clinical trials

Suffering from Duchenne muscular dystrophy, a neuromuscular disease that is now incurable, Benjamin, 10, is one of the ambassadors of Téléthon 2022. Genethon recently launched a gene therapy trial for this disease.

(read more)

Telethon 2022: for Lucie, “a real opportunity, thanks to advances in research”

Lucie has spinal muscular atrophy. A year ago, she was able to benefit from a gene therapy treatment based on technologies developed at Genethon. Lucie and her parents will be ambassadors of the 2022 Telethon.

(read more)

Publication: Genethon helps clarify a molecular mechanism of mitochondrial malfunction in Duchenne muscular dystrophy

Several laboratories, including Généthon, have begun gene therapy clinical trials for Duchenne muscular dystrophy. Research must be conducted, however, to improve the therapeutic benefit of future treatments for this rare genetic disease. 

(read more)

Publication: Genethon helps identify two vectors optimized for muscles via a European H2020 program

Making gene therapy vectors more specific is a major challenge in gene therapy. Edith Renaud-Gabardos, under the direction of Ana Buj-Bello, an Inserm Research Director, and several other Genethon collaborators, co-authored a publication in Science Advances demonstrating the optimized effectiveness of two capsids for muscle… (read more)

First Patient Dosed in Phase 1/2 Clinical Trial in Europe of Gene Therapy for LGMD-R9

Study to treat FKRP-related limb-girdle muscular dystrophy type 2I/R9 represents 30 years of research and is being conducted by Genethon spinout Atamyo Therapeutics.

(read more)

Meeting with Jessica Cartigny, Purification Design Engineer at Genethon

When she arrived in 2016, Jessica was drawn to Genethon for its human values. She began in the position of lab technician. Six years later, she is now a purification design engineer and is flourishing within a dynamic and compassionate team.

(read more)

The Genethon platforms obtain ISO 9001 certification

As of July 8, 2022, the Imaging-Cytometry, Preclinical Evaluation and Technological Development platforms have been officially ISO 9001 certified. An additional guarantee of the quality of the activities of these platforms.

(read more)

Anne Galy receives the WAS Foundation Callahan Award for her work on Wiskott-Aldrich syndrome

The WAS Foundation awarded the Callahan Prize for outstanding service to Anne Galy, head of the Immunology and biotherapies team. She has worked for more than 20 years on Wiskott-Aldrich syndrome, a severe immune deficiency of genetic origin.

(read more)

Sickle-cell anemia: a project involving the Gene editing team has just secured European funding

The “EDITSCD” project, that aims to improve gene editing strategies for sickle-cell anemia, this hereditary disease of the red blood cells, has just been selected by the European Union. It will involve a dozen or so research laboratories in Europe, among then the Gene editing team (Inserm UMR 951) headed by Mario Amendola at… (read more)

Meeting with Justine Klonowski, legal manager at Genethon

Recently promoted to legal manager at Genethon, Justine Klonowski plays a key role in the development of contracts between Genethon and its partners. She says she is proud to be part of the work of this atypical lab.

(read more)

Emanuèle BOURGES and Joëlle CHEUZEVILLE, USP engineers, a key role in drug production

Contrasting profiles of Emanuèle and Joëlle, both USP development engineers (cell culture processes) in Genethon’s Technology Development Department. Although they work in the same role, they each live the Genethon adventure in their own way.

(read more)

Gene Therapies Continue to Emerge as Effective Treatments for Rare Diseases, But Complex Challenges Remain

To mark International Rare Disease Day, Genethon identifies the most urgent priorities in overcoming these obstacles.

(read more)

Five post-doctoral positions open at Genethon, a leader in gene therapy for rare diseases

A pioneer and leader in gene therapy for rare disease, Genethon, a non-profit organization, recruits 5 post-doctoral fellow to develop research projects the Inserm-Genethon-UEVE Integrare unit.

(read more)

Genethon’s Lentiviral Vector-Based Gene Therapy Demonstrates Long-Term Safety and Efficacy for Wiskott-Aldrich Syndrome

Genethon announced that its lentiviral based gene therapy, developed in collaboration with French and British teams, has demonstrated long-term efficacy in eight patients with Wiskott-Aldrich syndrome, a rare and severe immune deficiency.

(read more)

From 2021, a seminal year for Genethon, to 2022, a year of challenges

After a year of significant breakthroughs in 2021, 2022 sees Genethon continuing its efforts in face of the medical and technological challenges of gene therapy for rare diseases, helping patients and their families.

(read more)